Efficacy and safety of saxagliptin in Japanese patients with type 2 diabetes - Two multi-centre, randomized, double-blind, placebo-controlled studies

Japanese Pharmacology and Therapeutics

Volumn 42, Issue 7, 2014, Pages 503-518

  Seino, Yutaka ^a  

^a KANSAI ELECTRIC POWER CO   (Japan)

Author keywords

Inhibitor of dipeptidyl peptidase 4; Placebo controlled; Saxagliptin; Type 2 diabetes

Indexed keywords

HEMOGLOBIN A1C; PLACEBO; SAXAGLIPTIN;

ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; HUMAN; HYPOGLYCEMIA; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MONOTHERAPY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

EID: 84906243862     PISSN: 03863603     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Chan JCN, Malic V, Jia W, Kadowaki T, Yajnik CS, Hu FB. Diabetes in Asia : epidemiology, risk factors, and pathophysiology. JAMA 2009; 301 : 2129-40.
2. Fukushima M, Suzuki H, Seino Y. Insulin secretion capacity in the development from normal glucose tolerance to type 2 diabetes. Diabetes Res Clin Pract 2004; 66S : S37-43. (Pubitemid 39572582)
3. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352 : 837-53.
4. ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355 : 2427-43.
5. Meneghini L, Hirsch IB. Pharmacotherapies for diabetes management : an update for the practicing clinician. Semin Thorac Cardiovasc Sci 2006; 18 : 379-84.
6. Willms B, Werner J, Holst JJ, Orskov C, Creutzfelds W, Nauck MA. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal : effects of exogenous glucagon-like peptide-1 (GLP-1) - (7-36) amide in type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab 1996; 81 : 327-32.
7. Stonehouse AH, Darsow T, Maggs DG. Incretin-based therapie. J Diabetes. 2012; 4 : 55-67.
8. Wang A, Dorso C, Kopcho L, Locke G, Langish R, Harstad E. Potency, selectivity and prolonged binding of saxagliptin to DPP4 : maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating inhibitor. BMC Pharmacology 2012; 12 : 2.
9. Rosenstock J, Aguilar-Salinas C, Klein E, Nepal S, List J, Chen R. Effect of saxagliptin monotherapy in treatmentnaïve patients with type 2 diabetes. Curr Med Res Opin 2009; 25 : 2401-11.
10. Chacra AR, Tan GH, Apanovitch A, Ravichandran S, List J, Chen R. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes : a randomised controlled trial. Int J Clin Pract 2010; 63 : 1395-406.
11. Hollander PL, Li J, Frederich R, Allen E, Chen R. Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus. Diab Vasc Dis Res 2011; 8: 125-35.
12. Chacra AR, Tan GH, Ravichandran S, List J, Chen R. Safety and efficacy of saxagliptin in combination with sulphonylurea over 76 weeks. Diab Vasc Dis Res 2011; 8 : 150-9.
13. Kashiwagi A, Kasuga M, Araki E, Oka Y, Hanafusa T, Ito H, et al. International clinical harmonization of glycated hemoglobin in Japan : From Japan Diabetes Society to National Glycohemoglobin Standardization Program values. Diabetol Int 2012; 3 : 8-10.
14. Stenlöf K, Raz I, Neutel J, Ravichandran S, Berglind N, ChenR. Saxagliptin and metformin XR combination therapy provides glycemic control over 24 hours in patients with T2DM inadequately controlled with metformin. Curr Med Res Opin 2010; 26 : 2355-63.
15. DeFronzo RA, Hissa MN, Garber AJ, Luiz Gross J, Yuyan Duan R, Ravichandran S, et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care. 2009; 32 : 1649-55.
16. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 2007; 87 : 1409-39. (Pubitemid 350041474)
17. Poucher SM, Cheetham S, Francis J, Zinker B, Kirby M, Vickers SP. Effects of saxagliptin and sitagliptin on glycaemic control and pancreatic β-cell mass in a streptozotocin-induced mouse model of type 2 diabetes. Diabetes Obes Metab 2012; 14 : 918-26.
18. Rustenbeck I. Desensitization of insulin secretion. Biochem Pharmacol 2002; 63 : 1921-35.
19. Karyekar C, Ravichandran S, Allen E, Fleming D. Frederich R. Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged≥65 years) with inadequately controlled type 2 diabete mellitus. Clin Intern Aging 2013; 8 : 419-30.
20. Nowicki M, Rychlik I, Haller H, Warren ML, Suchower L, Gause-Nilsson I. Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment. Diabetes Obes Metab 2011; 13 (6) : 523-32.
21. Goto A, Arah OA, Goto M, Terauchi Y, Noda M. Severe Hypoglycaemia and cardiovascular disease : Systematic review and meta-analysis with bias analysis. BMJ 2013; 347 : f4533.
22. Desouza CV, Bolli CB, Fonseca V. Hypoglycemia, diabetes, and cardiovascular events. DiabetesCare2010; 33 : 1389-94.
23. Bremer JP, Schmid S, Jauch-Chara K, Schulte B, Hallschmid M. Hypoglycemia unawareness in older compared with middle-aged patients with type 2 diabetes. Diabetes Care 2009; 32 : 1513-7.
24. Yaffe K, Falvey CM, Hamilton N, Harris TB, Simonsick EM, Strotmeyer ES, et al. Association between hypoglycemia and dementia in a biracial cohort of older adults with diabetes mellitus. JAMA Intern Med 2013; 173 : 1300-6.
25. Curkendall S, Thomas N, Bell KF, Juneau PL, Weiss A. Predictors of medication adherence in patients with type 2 diabete mellitus. Curr Med Res Opin 2013; 29 : 1275-86.